Huguenin P, Cochet B, Balant L, Loizeau E
Schweiz Med Wochenschr. 1978 Feb 11;108(6):206-14.
D-xylose pharmacokinetics has been studied in 6 healthy subjects by serial measurement of blood and urinary levels following oral and intravenous administration of two doses of D-xylose (5 and 25 g successively). Furthermore, patients with obesity, renal or hepatic insufficiency, or with a T-drain after cholecystectomy, are also investigated. Both the rate and completeness of D-xylose absorption and the apparent distribution volume of D-xylose present noteworthy interindividual variations, so that the time and value of the peak blood level are highly variable as between healthy subjects. Renal insufficiency increases the apparent elimination half-life of D-xylose and notably reduces D-xylose renal excretion. This study provides pharmacokinetic evidence of the very wide range of blood and urinary levels observed in the D-xylose tolerance test, and emphasizes the fact that D-xylose urinary excretion alone is not a reliable index of intestinal absorption.
通过对6名健康受试者口服和静脉注射两剂D-木糖(先后为5克和25克)后连续测量血液和尿液水平,研究了D-木糖的药代动力学。此外,还对肥胖、肾功能或肝功能不全患者,或胆囊切除术后有T型引流管的患者进行了研究。D-木糖吸收的速率和完全程度以及D-木糖的表观分布容积均存在显著的个体间差异,因此健康受试者之间血药浓度峰值出现的时间和数值变化很大。肾功能不全会延长D-木糖的表观消除半衰期,并显著减少D-木糖的肾排泄。本研究提供了药代动力学证据,证明在D-木糖耐量试验中观察到的血液和尿液水平范围非常广泛,并强调仅D-木糖尿排泄不是肠道吸收的可靠指标这一事实。